{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T03:09:04Z","timestamp":1780369744709,"version":"3.54.1"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:00:00Z","timestamp":1744848000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005088","name":"Beijing Municipal Health Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005088","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010270","name":"Capital Health Research and Development of Special Fund","doi-asserted-by":"publisher","award":["2022-4-2125"],"award-info":[{"award-number":["2022-4-2125"]}],"id":[{"id":"10.13039\/501100010270","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.schres.2025.04.011","type":"journal-article","created":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T12:21:20Z","timestamp":1745065280000},"page":"76-84","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Aripiprazole or metformin for hyperprolactinemia in women with schizophrenia: A 6-month, real-world chart review study"],"prefix":"10.1016","volume":"280","author":[{"given":"Jie","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuequan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haochu","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunjing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph U.","family":"Correll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1\u20132","key":"10.1016\/j.schres.2025.04.011_bb0005","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.brainres.2003.09.082","article-title":"The novel antipsychotic aripiprazole is a partial agonist at short and long isoforms of D2 receptors linked to the regulation of adenylyl cyclase activity and prolactin release","volume":"1003","author":"Aihara","year":"2004","journal-title":"Brain Res."},{"key":"10.1016\/j.schres.2025.04.011_bb0010","series-title":"Assessment of Monitoring and Management Practices of Antipsychotic-induced Hyperprolactinemia at a Medical City in Riyadh","author":"Alshabeeb","year":"2024"},{"issue":"11","key":"10.1016\/j.schres.2025.04.011_bb0015","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s11920-023-01460-6","article-title":"Evidence-based recommendations for the pharmacological treatment of women with schizophrenia spectrum disorders","volume":"25","author":"Brand","year":"2023","journal-title":"Curr. Psychiatry Rep."},{"issue":"1","key":"10.1016\/j.schres.2025.04.011_bb0020","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s12955-021-01723-x","article-title":"Health state utility values in major depressive disorder treated with pharmacological interventions: a systematic literature review","volume":"19","author":"Brockbank","year":"2021","journal-title":"Health Qual. Life Outcomes"},{"issue":"8","key":"10.1016\/j.schres.2025.04.011_bb0025","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.pnpbp.2010.08.012","article-title":"Differential add-on effects of aripiprazole in resolving hyperprolactinemia induced by risperidone in comparison to benzamide antipsychotics","volume":"34","author":"Chen","year":"2010","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.schres.2025.04.011_bb0030","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.psyneuen.2015.04.011","article-title":"Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: A randomized, double-blind, placebo-controlled, dose-response study","volume":"58","author":"Chen","year":"2015","journal-title":"Psychoneuroendocrinology"},{"issue":"2","key":"10.1016\/j.schres.2025.04.011_bb0035","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/YIC.0000000000000106","article-title":"Effect of aripiprazole lauroxil on agitation and hostility in patients with schizophrenia","volume":"31","author":"Citrome","year":"2016","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"9","key":"10.1016\/j.schres.2025.04.011_bb0040","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1001\/jama.2018.10136","article-title":"Real-world evidence and real-world data for evaluating drug safety and effectiveness","volume":"320","author":"Corrigan-Curay","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.schres.2025.04.011_bb0045","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1471-244X-12-20","article-title":"A patient perspective of the impact of medication side effects on adherence: results of a cross-sectional nationwide survey of patients with schizophrenia","volume":"12","author":"Dibonaventura","year":"2012","journal-title":"BMC Psychiatry"},{"issue":"5","key":"10.1016\/j.schres.2025.04.011_bb0050","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1097\/JCP.0000000000000543","article-title":"Risk of extrapyramidal adverse events with aripiprazole","volume":"36","author":"Etminan","year":"2016","journal-title":"J. Clin. Psychopharmacol."},{"issue":"2 Suppl","key":"10.1016\/j.schres.2025.04.011_bb0055","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1177\/0269216307087148","article-title":"Prolactin and dopamine: what is the connection? A review article","volume":"22","author":"Fitzgerald","year":"2008","journal-title":"J. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.schres.2025.04.011_bb0060","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/wps.20387","article-title":"Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis","volume":"16","author":"Galling","year":"2017","journal-title":"World psychiatry : official journal of the World Psychiatric Association (WPA)"},{"issue":"22","key":"10.1016\/j.schres.2025.04.011_bb0065","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1007\/s00213-017-4730-6","article-title":"Antipsychotic-induced hyperprolactinemia: synthesis of world-wide guidelines and integrated recommendations for assessment, management and future research","volume":"234","author":"Grigg","year":"2017","journal-title":"Psychopharmacology"},{"issue":"5","key":"10.1016\/j.schres.2025.04.011_bb0070","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/00131746-200309000-00003","article-title":"Hyperprolactinemia and schizophrenia: mechanisms and clinical aspects","volume":"9","author":"Halbreich","year":"2003","journal-title":"J. Psychiatr. Pract."},{"issue":"5","key":"10.1016\/j.schres.2025.04.011_bb0075","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1517\/14740338.2014.906579","article-title":"Second-generation and newly approved antipsychotics, serum prolactin levels and sexual dysfunctions: a critical literature review","volume":"13","author":"Hert","year":"2014","journal-title":"Expert Opin. Drug Saf."},{"issue":"6","key":"10.1016\/j.schres.2025.04.011_bb0080","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1517\/14740338.2016.1167873","article-title":"Relationship between antipsychotic medication, serum prolactin levels and osteoporosis\/osteoporotic fractures in patients with schizophrenia: a critical literature review","volume":"15","author":"Hert","year":"2016","journal-title":"Expert Opin. Drug Saf."},{"issue":"4","key":"10.1016\/j.schres.2025.04.011_bb0085","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/JCP.0000000000000898","article-title":"Adjunct aripiprazole reduces prolactin and prolactin-related adverse effects in premenopausal women with psychosis: results from the DAAMSEL clinical trial","volume":"38","author":"Kelly","year":"2018","journal-title":"J. Clin. Psychopharmacol."},{"issue":"Suppl. 2","key":"10.1016\/j.schres.2025.04.011_bb0090","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0306-4530(02)00127-0","article-title":"Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone","volume":"28","author":"Kinon","year":"2003","journal-title":"Psychoneuroendocrinology"},{"issue":"5","key":"10.1016\/j.schres.2025.04.011_bb0095","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/YCO.0b013e328355e1ac","article-title":"Osteoporosis and fracture risk in people with schizophrenia","volume":"25","author":"Kishimoto","year":"2012","journal-title":"Curr. Opin. Psychiatry"},{"issue":"9","key":"10.1016\/j.schres.2025.04.011_bb0100","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.jaac.2023.03.007","article-title":"Antipsychotic-related prolactin levels and sexual dysfunction in mentally ill youth: A 3-month cohort study","volume":"62","author":"Koch","year":"2023","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2025.04.011_bb0105","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1007\/s12020-014-0428-2","article-title":"The effect of short-term metformin treatment on plasma prolactin levels in bromocriptine-treated patients with hyperprolactinaemia and impaired glucose tolerance: a pilot study","volume":"49","author":"Krysiak","year":"2015","journal-title":"Endocrine"},{"issue":"5","key":"10.1016\/j.schres.2025.04.011_bb0110","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1111\/jcpt.13470","article-title":"The impact of metformin on prolactin levels in postmenopausal women","volume":"46","author":"Krysiak","year":"2021","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.schres.2025.04.011_bb0115","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.schres.2017.03.019","article-title":"Predictors of menstruation restoration during metformin administration for treatment of antipsychotic drug-induced amenorrhea: A post hoc analysis","volume":"190","author":"Li","year":"2017","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.schres.2025.04.011_bb0120","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1186\/s12888-022-04008-9","article-title":"Place of the partial dopamine receptor agonist aripiprazole in the management of schizophrenia in adults: a Delphi consensus study","volume":"22","author":"Llorca","year":"2022","journal-title":"BMC Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2025.04.011_bb0125","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/s41398-022-02027-4","article-title":"Pharmacological treatment strategies for antipsychotic-induced hyperprolactinemia: a systematic review and network meta-analysis","volume":"12","author":"Lu","year":"2022","journal-title":"Transl. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2025.04.011_bb0130","first-page":"65","article-title":"ICD-10: international statistical classification of diseases and related health problems : tenth revision","volume":"56","author":"Organization","year":"2010","journal-title":"Acta Chir. Iugosl."},{"issue":"1","key":"10.1016\/j.schres.2025.04.011_bb0135","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1677\/joe.1.05844","article-title":"Insulin sensitizing drugs increase the endogenous dopaminergic tone in obese insulin-resistant women with polycystic ovary syndrome","volume":"184","author":"Ortega-Gonz\u00e1lez","year":"2005","journal-title":"J. Endocrinol."},{"issue":"2","key":"10.1016\/j.schres.2025.04.011_bb0140","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.bpobgyn.2007.08.002","article-title":"Hyperprolactinaemia","volume":"22","author":"Prabhakar","year":"2008","journal-title":"Best Pract. Res. Clin. Obstet. Gynaecol."},{"issue":"1","key":"10.1016\/j.schres.2025.04.011_bb0145","doi-asserted-by":"crossref","first-page":"38","DOI":"10.4103\/IJPSYM.IJPSYM_147_17","article-title":"Add-on aripiprazole for atypical antipsychotic-induced, clinically significant hyperprolactinemia","volume":"40","author":"Raveendranthan","year":"2018","journal-title":"Indian J. Psychol. Med."},{"issue":"10","key":"10.1016\/j.schres.2025.04.011_bb0150","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1093\/ajhp\/zxab065","article-title":"Guidance on the treatment of antipsychotic-induced hyperprolactinemia when switching the antipsychotic is not an option","volume":"78","author":"Rusgis","year":"2021","journal-title":"Am. J. Health Syst. Pharm."},{"issue":"9","key":"10.1016\/j.schres.2025.04.011_bb0155","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1176\/appi.ajp.2007.06071075","article-title":"Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial","volume":"164","author":"Shim","year":"2007","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2025.04.011_bb0160","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1186\/s12888-016-1049-5","article-title":"Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis","volume":"16","author":"Silva","year":"2016","journal-title":"BMC Psychiatry"},{"issue":"8","key":"10.1016\/j.schres.2025.04.011_bb0165","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1176\/appi.ajp.2012.12050591","article-title":"Metformin as a treatment for antipsychotic drug side effects: special focus on women with schizophrenia","volume":"169","author":"Smith","year":"2012","journal-title":"Am. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2025.04.011_bb0170","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s00213-006-0621-y","article-title":"Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT 2A receptors: functional receptor-binding and in vivo electrophysiological studies","volume":"190","author":"Stark","year":"2007","journal-title":"Psychopharmacology"},{"issue":"10","key":"10.1016\/j.schres.2025.04.011_bb0175","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S2215-0366(21)00241-8","article-title":"Antipsychotic use and risk of breast cancer in women with schizophrenia: a nationwide nested case-control study in Finland","volume":"8","author":"Taipale","year":"2021","journal-title":"Lancet Psychiatry"},{"issue":"5","key":"10.1016\/j.schres.2025.04.011_bb0180","doi-asserted-by":"crossref","first-page":"681","DOI":"10.2174\/1570159X13666150115220221","article-title":"The incidence of akathisia in the treatment of schizophrenia with aripiprazole, asenapine and Lurasidone: A meta-analysis","volume":"13","author":"Thomas","year":"2015","journal-title":"Curr. Neuropharmacol."},{"issue":"4","key":"10.1016\/j.schres.2025.04.011_bb0185","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/ppc.12050","article-title":"Frequency of hyperprolactinemia and its associations with demographic and clinical characteristics and antipsychotic medications in psychiatric inpatients in China","volume":"50","author":"Wang","year":"2014","journal-title":"Perspect. Psychiatr. Care"},{"issue":"8","key":"10.1016\/j.schres.2025.04.011_bb0190","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1176\/appi.ajp.2012.11091432","article-title":"Metformin for treatment of antipsychotic-induced amenorrhea and weight gain in women with first-episode schizophrenia: a double-blind, randomized, placebo-controlled study","volume":"169","author":"Wu","year":"2012","journal-title":"Am. J. Psychiatry"},{"issue":"5","key":"10.1016\/j.schres.2025.04.011_bb0195","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1097\/JCP.0b013e3181ee832d","article-title":"Dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia","volume":"30","author":"Yasui-Furukori","year":"2010","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2025.04.011_bb0200","first-page":"1","article-title":"Comparing the effects of peripheral nerve block and general anesthesia with general anesthesia alone on postoperative delirium and complications in elderly patients: a retrospective cohort study using a nationwide database","volume":"0","author":"Yoshimura","year":"2022","journal-title":"Reg. Anesth. Pain Med."},{"key":"10.1016\/j.schres.2025.04.011_bb0205","article-title":"Efficacy and safety of adjunctive aripiprazole, metformin, and Paeoniae-Glycyrrhiza decoction for antipsychotic-induced hyperprolactinemia: A network Meta-analysis of randomized controlled trials","volume":"12","author":"Zhang","year":"2021","journal-title":"Front. Psychol."},{"issue":"5","key":"10.1016\/j.schres.2025.04.011_bb0210","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1177\/0269881117699630","article-title":"Adjunctive metformin for antipsychotic-related hyperprolactinemia: A meta-analysis of randomized controlled trials","volume":"31","author":"Zheng","year":"2017","journal-title":"Journal of psychopharmacology (Oxford, England)"},{"key":"10.1016\/j.schres.2025.04.011_bb0215","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.schres.2021.08.013","article-title":"Prolactin levels influenced by antipsychotic drugs in schizophrenia: A systematic review and network meta-analysis","volume":"237","author":"Zhu","year":"2021","journal-title":"Schizophr. Res."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996425001343?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996425001343?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T14:31:55Z","timestamp":1774881115000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996425001343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":43,"alternative-id":["S0920996425001343"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2025.04.011","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aripiprazole or metformin for hyperprolactinemia in women with schizophrenia: A 6-month, real-world chart review study","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2025.04.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}